Pediatric Liver Transplant Complications: EBV-Associated Tumors and Infection Management Strategies
American Journal of Case Reports · 2025
DOI: 10.12659/ajcr.948566 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Case Reports, 2025. Verfasst von Li-Na Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Liver Disease, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical Universi…. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Liver Transplantation, Lymphoproliferative Disorders, Postoperative Complications. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND EBV-associated smooth muscle tumors (EBV-SMTs) are rare malignancies in pediatric transplant recipients under chronic immunosuppression, with fewer than100 cases reported globally. Diagnosis is challenging due to nonspecific imaging findings and overlapping features with other post-transplant malignancies, necessitating histopathological confirmation. This underscores the need for heightened clinical suspicion in high-risk cohorts. CASE REPORT Here, we present a pediatric case from our liver transplant (LT) center involving a patient who developed both post-transplant lymphoproliferative disorder (PTLD) and EBV-SMT following liver transplantation. Clinical data and comprehensive treatment details of this rare case were retrospectively reviewed. The patient, diagnosed with a congenital bile acid synthesis defect, underwent liver transplantation at the age of 5 months. Pre-transplant screening confirmed that both the donor and recipient were negative for cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections. However, EBV DNA became detectable in peripheral blood at 22.5 months after transplantation and showed a progressive increase over time. At 30.9 months after LT, PTLD and hepatic EBV-SMT were simultaneously diagnosed through histopathological examination. Treatment strategies included stepwise immunosuppression reduction, administration of rituximab targeting PTLD, and subsequent sirolimus therapy for EBV-SMT and surgical resection of the liver and splenic tumor. This multidisciplinary approach successfully achieved complete remission. CONCLUSIONS EBV-SMT necessitates multidisciplinary management balancing immunosuppression with targeted therapies. mTOR inhibitors are a strategic option for concurrent rejection prevention and tumor control. Sirolimus, a mechanistic target of rapamycin (mTOR) inhibitor, demonstrates promise by simultaneously preventing rejection and inhibiting tumor progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Critical Liver Disease, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Laboratory for Clinical Medicine, Capital Medical University, Beijing, China.
- State Key Laboratory of Digestive Health, Beijing, China.
- Beijing Key Laboratory of Tolerance Induction and Organ Protection in Transplantation, Beijing, China.
- Liver Transplantation Center, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Laboratory for Clinical Medicine, Beijing, China.
ORCID-Profile: Jing-Yi Liu
Zitieren
APA
Wu, L. N., Zeng, Z. G., Liu, J. Y., Wei, L., Tan, Y. L., Xie, F. X., Zhu, Z. J., & Sun, L. Y. (2025). Pediatric Liver Transplant Complications: EBV-Associated Tumors and Infection Management Strategies. American Journal of Case Reports. https://doi.org/10.12659/ajcr.948566
Vancouver
Wu LN, Zeng ZG, Liu JY, Wei L, Tan YL, Xie FX, et al. Pediatric Liver Transplant Complications: EBV-Associated Tumors and Infection Management Strategies. American Journal of Case Reports. 2025. doi:10.12659/ajcr.948566
BibTeX
@article{Wu2025,
author = {Wu, Li-Na and Zeng, Zhi-Gui and Liu, Jing-Yi and Wei, Lin and Tan, Yu-Le and Xie, Fu-Xiao and Zhu, Zhi-Jun and Sun, Li-Ying},
title = {Pediatric Liver Transplant Complications: EBV-Associated Tumors and Infection Management Strategies},
journal = {American Journal of Case Reports},
year = {2025},
doi = {10.12659/ajcr.948566}
}
EUVIMED